ROIV - Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal | Benzinga
Roche Holding AG (OTC: RHHBY) inked a deal to acquire Telavant Holdings, Inc. for $7.1 billion.
As per the terms, Roche will pay a purchase price upfront, along with a near-term milestone payment of $150 million.
Telavant was jointly formed by Roivant Sciences Ltd (NASDAQ: ROIV) and Pfizer Inc (NYSE: PFE) in 2022 to develop and commercialize RVT-3101 in the U.S. and Japan.
RVT-3101, a novel TL1A-directed antibody, is a new therapy for people suffering from ...